Related Experiment Video
Updated: Jul 17, 2026

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils
Published on: September 28, 2019
Ganglioside G(M1)-mediated amyloid-beta fibrillogenesis and membrane disruption
Eva Y Chi1, Shelli L Frey, Ka Yee C Lee
1Department of Chemistry, The Institute for Biophysical Dynamics, and the James Franck Institute, University of Chicago, 929 E. 57th Street, Chicago, Illinois 60637, USA.
Abstract:
There is increasing evidence that a class of cell membrane glycolipids, gangliosides, can mediate the fibrillogenesis and toxicity of Alzheimer's disease amyloid-beta peptide (Abeta). Using lipid monolayers and vesicles as model membranes, we measured the insertion of Abeta into 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)-ganglioside GM1 monolayers to probe Abeta-GM1 interactions, imaged the effects of Abeta insertion on monolayer morphology, and measured the rate of Abeta fibril formation when incubated with 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)-GM1 vesicles. Furthermore, the location of Abeta association in the monolayer was assessed by dual-probe fluorescence experiments. Abeta exhibited direct and favorable interactions with GM1 as Abeta insertion monotonically increased with GM1 concentration, despite increases in monolayer rigidity at low GM1 levels. At low GM1 concentrations, Abeta preferentially inserted into the disordered, liquid expanded phase. At higher GM1 concentrations, Abeta inserted more uniformly into the monolayer, resulting in no detectable preferences for either the disordered or condensed phase. Abeta insertion led to the disruption of membrane morphology, specifically to the expansion of the disordered phase at low GM1 concentrations and significant disruption of the condensed domains at higher GM1 concentrations. During incubation with POPC vesicles containing physiological levels of GM1, the association of Abeta with vesicles seeded the formation of Abeta fibrils. In conclusion, favorable interactions between Abeta and GM1 in the cell membrane may provide a mechanism for Abeta fibrillogenesis in vivo, and Abeta-induced disruption of the cell membrane may provide a pathway by which Abeta exerts toxicity.
Insights
Gangliosides, like GM1, directly interact with amyloid-beta (Abeta) in cell membranes, promoting Alzheimer's disease fibril formation and toxicity. These findings suggest a key mechanism for Abeta aggregation and cellular damage in vivo.
Area of Science:
- Neuroscience
- Biochemistry
- Cell Biology
Background:
- Gangliosides are cell membrane glycolipids implicated in Alzheimer's disease pathogenesis.
- Amyloid-beta peptide (Abeta) aggregation and toxicity are central to Alzheimer's disease.
- The role of gangliosides in Abeta fibrillogenesis and toxicity requires further elucidation.
Purpose of the Study:
- To investigate the direct interactions between Abeta and ganglioside GM1 in model cell membranes.
- To determine how Abeta-GM1 interactions influence Abeta fibril formation and membrane morphology.
- To explore the potential mechanisms of Abeta toxicity mediated by cell membrane components.
Main Methods:
- Utilized lipid monolayers and vesicles composed of DPPC/POPC and GM1 to model cell membranes.
- Measured Abeta insertion into model membranes using fluorescence and imaged morphological changes.
- Assessed Abeta fibril formation rates and localization within membranes via dual-probe fluorescence.
Main Results:
- Abeta exhibited direct, concentration-dependent insertion into GM1-containing membranes, favoring disordered phases at low GM1 concentrations.
- Abeta insertion disrupted membrane morphology, altering domain expansion and condensation.
- Abeta association with GM1-containing vesicles seeded the formation of Abeta fibrils.
Conclusions:
- Favorable interactions between Abeta and GM1 in cell membranes may drive Abeta fibrillogenesis in vivo.
- Abeta-induced disruption of membrane integrity offers a potential pathway for Abeta-mediated cellular toxicity.
- Targeting Abeta-ganglioside interactions could be a therapeutic strategy for Alzheimer's disease.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Proteoglycans
Oligosaccharide Assembly
Multiple sugar molecules that may or may...

